HLA typing market for oncology immunotherapy seen reaching $1.79B by 2030

By AI, Created 4:56 PM UTC, May 18, 2026, /AGP/ – The market for human leukocyte antigen typing in oncology immunotherapy is projected to keep expanding as personalized cancer treatment, companion diagnostics and clinical research accelerate. The Business Research Company forecast the market will nearly double from 2025 levels by 2030, with North America leading now and Asia-Pacific growing fastest.

Why it matters: - HLA typing helps match oncology immunotherapy to a patient’s immune profile, which can improve treatment fit and reduce immune-related side effects. - Demand is rising alongside personalized medicine, cell and gene therapy development, and more biomarker-driven cancer care. - The market’s growth signals broader adoption of precision oncology tools in clinical practice and research.

What happened: - The Business Research Company projected the global human leukocyte antigen typing market for oncology immunotherapy will grow from $1.22 billion in 2025 to $1.31 billion in 2026. - The market is forecast to reach $1.79 billion by 2030. - The report puts the market’s 2025-2026 CAGR at 7.8% and its 2026-2030 CAGR at 8.0%. - The company released the forecast in its Human Leukocyte Antigen (HLA) Typing Global Market Report 2026. - The report covers market size, trends and forecasts for 2026-2035. - The release date was May 15, 2026. - Download a free sample of the report. - View the full market report.

The details: - The report links market growth to rising global cancer incidence. - PCR and sequencing advances are expanding the use of HLA typing. - Precision oncology adoption is increasing. - Clinical research focused on immunotherapies is growing. - Biomarker-driven treatment strategies are spreading. - The report expects more cell and gene therapy candidates to lift demand. - Personalized immunotherapy research is attracting more investment. - Companion diagnostics are becoming more important. - Oncology clinical trials are broadening worldwide. - Regulatory support for precision medicine is improving. - The report highlights next-generation sequencing-based HLA typing as a major trend. - HLA profiling is being integrated into adoptive T-cell therapies. - High-resolution HLA typing is gaining use in clinical trials. - Personalized cancer vaccine development is accelerating. - Predictive immune compatibility testing is drawing more attention. - HLA typing is a genetic test that identifies a patient’s unique HLA profile and helps guide personalized cancer immunotherapies. - The testing can help predict treatment efficacy and support better overall outcomes in precision oncology. - In February 2024, the Personalized Medicine Coalition reported the FDA approved 16 personalized treatments in 2023, up from 6 in 2022, including 7 cancer drugs and 3 therapies for other conditions.

Between the lines: - The market outlook reflects a shift from broad cancer treatment toward more individualized therapy selection. - The forecast suggests HLA typing is moving from a specialized lab tool to a more routine piece of the immunotherapy workflow. - The strongest growth areas appear tied to therapies and trials that need tighter immune matching.

What’s next: - North America held the largest market share in 2025. - Asia-Pacific is expected to grow the fastest over the next several years. - The report also tracks markets in South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Wider use of sequencing-based typing and companion diagnostics is likely to shape the next phase of growth. - More regulatory support and more personalized therapy approvals could further expand demand.

The bottom line: - HLA typing is becoming a bigger commercial piece of oncology immunotherapy as personalized cancer care moves deeper into mainstream medicine.